Efficacy and safety of postoperative bio-chemoradiotherapy using cetuximab and docetaxel for high-risk head and neck cancer patients in Japan

[1] Cooper JS(2004)Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck N Engl J Med 350 1937-1944

[2] Pajak TF(2004)Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer N Engl J Med 350 1945-1952

[3] Forastiere AA(2005)Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG #9501) Head Neck 27 843-850

[4] Bernier J(2014)Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: radiation therapy oncology group RTOG-0234 J Clin Oncol 32 2486-2495

[5] Domange C(2007)Decrease of creatinine clearance rate with ageing in patients with head and neck cancer in Japan Int J Clin Oncol 12 120-124

[6] Ozsahin M(2015)Cancer incidence and incidence rate in Japan in 2009: a study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project Jpn J Clin Oncol 45 884-891

[7] Bernier J(1991)Randomized study of preoperative versus postoperative radiation therapy in advanced head and neck carcinoma: long-term follow-up of RTOG study 73-03 Int J Radiat Oncol Biol Phys 20 21-28

[8] Cooper JS(1993)Evaluation of the dose for postoperative radiation therapy of head and neck cancer: first report of a prospective randomized trial Int J Radiat Oncol Biol Phys 26 3-11

[9] Pajak TF(2006)Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck N Engl J Med 354 567-578

[10] Harari PM(2010)Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival Lancet Oncol 11 21-28

[1] Cooper JS(2004)Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck N Engl J Med 350 1937-1944

[2] Pajak TF(2004)Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer N Engl J Med 350 1945-1952

[3] Forastiere AA(2005)Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG #9501) Head Neck 27 843-850

[4] Bernier J(2014)Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: radiation therapy oncology group RTOG-0234 J Clin Oncol 32 2486-2495

[5] Domange C(2007)Decrease of creatinine clearance rate with ageing in patients with head and neck cancer in Japan Int J Clin Oncol 12 120-124

[6] Ozsahin M(2015)Cancer incidence and incidence rate in Japan in 2009: a study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project Jpn J Clin Oncol 45 884-891

[7] Bernier J(1991)Randomized study of preoperative versus postoperative radiation therapy in advanced head and neck carcinoma: long-term follow-up of RTOG study 73-03 Int J Radiat Oncol Biol Phys 20 21-28

[8] Cooper JS(1993)Evaluation of the dose for postoperative radiation therapy of head and neck cancer: first report of a prospective randomized trial Int J Radiat Oncol Biol Phys 26 3-11

[9] Pajak TF(2006)Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck N Engl J Med 354 567-578

[10] Harari PM(2010)Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival Lancet Oncol 11 21-28